Skip to main content
AMCP 2025 Main banner

Drugs, Diseases, and the Managed Care Impact

(D5) Mind Over Migraines: Disease Burden, Innovative Therapies, and Managed Care Trends in Treating Migraines

Wednesday, April 2, 2025
2:30 PM - 3:45 PM CST
Location: 320
CPE
ACPE UAN:0233-0000-25-021-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
This activity is supported by an independent medical education grant from Pfizer, Inc.

Migraine is a complex, neurobiological disorder characterized by recurrent and often debilitating headaches, typically affecting one side of the head, accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound. New therapies, such as monoclonal antibodies acting on CGRP or its receptors, offer promising improvements in migraine prevention and treatment, leading to important considerations for managed care organizations on integrating these advancements into practice and structuring pharmacy benefit design accordingly.

This session will provide insights into the multifaceted nature and accompanying health conditions of migraines, their burden on an individual’s quality of life, and effective treatment methodologies that can be integrated into formulary coverage policies and design. Additionally, this session will review current utilization patterns, identify shortcomings in existing benefit structures, and discover methods to evaluate valuable coverage strategies to improve migraine health outcomes for a diverse population.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Examine the migraine disease burden to evaluate the significance of treatment outcomes.
  2. Explain the role of calcitonin gene-related peptide (CGRP) receptor antagonists in the acute and preventative management of migraine.
  3. Identify emerging evidence supporting innovative pipeline migraine treatment modalities.
  4. Discuss managed care strategies to ensure timely and equitable access to essential migraine therapies.